Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
CpG island hypermethylation has been recognized as an alternative mechanism for tumor suppressor gene inactivation. In this study, we performed methylation-specific PCR (MSP) to investigate the methylation status of 10 selected tumor suppressor genes in neuroblastoma. Seven of the investigated genes (CD44, RASSF1A, CASP8, PTEN, ZMYND10, CDH1, PRDM2) showed high frequencies (> or =30%) of methylation in 33 neuroblastoma cell lines. In 42 primary neuroblastoma tumors, the frequencies of methylation were 69%, CD44; 71%, RASSF1A; 56%, CASP8; 25%, PTEN; 15%, ZMYND10; 8%, CDH1; and 0%, PRDM2. Furthermore, CASP8 and CDH1 hypermethylation was significantly associated with poor event-free survival. Meta-analysis of 115 neuroblastoma tumors demonstrated a significant correlation between CASP8 methylation and MYCN amplification. In addition, there was a correlation between ZMYND10 methylation and MYCN amplification. The MSP data, together with optimized mRNA re-expression experiments (in terms of concentration and time of treatment and use of proper reference genes) further strengthen the notion that epigenetic alterations could play a significant role in NB oncogenesis. This study thus warrants the need for a global profiling of gene promoter hypermethylation to identify genome-wide aberrantly methylated genes in order to further understand neuroblastoma pathogenesis and to identify prognostic methylation markers.
Hoebeeck
Jasmien
J
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Michels
Evi
E
Pattyn
Filip
F
Combaret
Valérie
V
Vermeulen
Joëlle
J
Yigit
Nurten
N
Hoyoux
Claire
C
Laureys
Geneviève
G
De Paepe
Anne
A
Speleman
Frank
F
Vandesompele
Jo
J
D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D019175:DNA Methylation; D000077209:Decitabine; D044127:Epigenesis, Genetic; D016147:Genes, Tumor Suppressor; D016678:Genome; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007223:Infant; D009447:Neuroblastoma / Q000235:genetics* / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism
D006877:Hydroxamic Acids; D012333:RNA, Messenger; C012589:trichostatin A; D000077209:Decitabine; D001374:Azacitidine